openPR Logo
Press release

Cryptosporidiosis Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

04-08-2019 02:53 PM CET | Health & Medicine

Press release from: Pharma Proff

Cryptosporidiosis Therapeutics- Pipeline Analysis 2018,

Cryptosporidiosis is a severe form of illness caused by parasites of various Cryptosporidium species. A person can be infected by parasites by having contaminated food and water or coming in contact with contaminated places.

Download the sample report @ https://www.pharmaproff.com/request-sample/1058

Some of the symptoms observed in people with cryptosporidiosis are fever, nausea, vomiting, stomach pain, and weight loss. People with weakened immune system, acquired immunodeficiency syndrome (AIDS), cancer, or who have undergone a transplant are more likely to develop cryptosporidiosis.

Get the detailed analysis @ https://www.pharmaproff.com/report/cryptosporidiosis-therapeutics-pipeline-analysis

Some of the complications associated with cryptosporidiosis are severe dehydration, inflammation of the bile duct, and malnutrition.

Make Enquiry before purchase @ https://www.pharmaproff.com/enquiry/1058

This disease can be treated by fluid replacement therapy, anti-retroviral therapy, anti-motility agents, and anti-parasitic drugs. ioGenetics Inc. is in the process of developing DBAF201 for the treatment of cryptosporidiosis. Other than this Romark Laboratories L.C. is also involved in the cryptosporidiosis pipeline.

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cryptosporidiosis Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments here

News-ID: 1693343 • Views: 208

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Cryptosporidiosis

Animal Parasiticides Market - Bayer Animal Health and ParaTheraTech sign a globa …
Recent Developments Bayer AG is a German multinational pharmaceutical and life sciences company, it is a global enterprise with core competencies in the life science fields of health care and agriculture. Its products and services are designed to serve people and develop their quality of life. Bayer to strengthen its portfolio of products for farm animals with new Cryptosporidiosis treatment options obtained from ParaTheraTech. They signed a global license agreement to
Enteric Disease Testing Market 2018 To 2025 - Market Dynamics and SWOT Analysis …
The Enteric Disease Testing Market research report provided by Crystal Market Research (CMR) is the most detailed study about Enteric Disease Testing Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business. Enteric Disease Testing Market By Disease Indication, Testing Methods and End User - Global
Enteric Disease Testing Market (2017 - 2025) historical growth, Production Volum …
This report on enteric disease testing market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing test kits for enteric disease testing as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments
Enteric Disease Testing Market (Amebiasis, C.difficile Infection, Campylobacteri …
"The Report Enteric Disease Testing Market (Amebiasis, C.difficile Infection, Campylobacteriosis, Cholera, Cryptosporidiosis, E.coli Infection, Giardiasis, H.pylori Infection, Norovirus Infection, Rotavirus Infection, Salmonellosis and Shigellosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Infectious enteric diseases are usually caused by a variety of bacteria, viruses and parasites when they enter
Global Enteric Disease Testing Market Analysis: Bacterial-, Viral-, and Parasiti …
The global enteric disease testing market is estimated to reach USD 4.2 Billion in 2020, growing at a CAGR of 5.6% from 2016 to 2020, due to higher demand for molecular diagnostics worldwide. The global enteric disease testing market report focuses on the major diseases such as campylobacteriosis, salmonellosis, giardiasis, cryptosporidiosis, amebiasis, norovirus infection and clostridium difficile mediated infection. All age groups are susceptible to enteric diseases; however small children,
Enteric Disease Testing Market Size, Share, Trends, Analysis, Report & Forecast …
According to Stratistics MRC, the Global Enteric Disease Testing market is expected to grow from $3.86 billion in 2015 to reach $5.12 billion by 2022 with a CAGR of 4.1%. Enteric disease testing market is mainly driven by increasing technological advancements in the field of molecular diagnostics. Additionally, growing geriatric population coupled with unhygienic living conditions, and rising medical testing for enteric disease are the factors propelling the market growth.